Amgen's Q2 2010 earnings call highlights strong performance in new product launches, particularly Prolia, with signs of early success in both Europe and the US.  Management expresses confidence in handling healthcare reform and biosimilar competition.  However, foreign exchange headwinds and potential impacts from dialysis bundling provisions create uncertainty regarding short-term revenue guidance.
[1]
